Dopamine secretion by PC12 cells microencapsulated in a hydroxyethyl methacrylate-methyl methacrylate copolymer

Biomaterials

Volumn 17, Issue 3, 1996, Pages 267-275

  Roberts, Todd ^a   De Boni, Umberto ^b   Sefton, Michael V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dopamine; HEMA; Microencapsulation; PC12

Indexed keywords

COPOLYMER; FORMAZAN; MACROGOL 200; METHACRYLIC ACID; TETRAZOLIUM;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL STRAIN; CELL VIABILITY; DOPAMINE RELEASE; MICROENCAPSULATION; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRECIPITATION; PRIORITY JOURNAL; RAT; TIME; TISSUE CULTURE;

EID: 0030061765     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/0142-9612(96)85564-5     Document Type: Article

References (42)

1. Hornykiewics O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986; 45: 19-34.
2. Chase TN, Juncos J, Serrati C, Fabbrini G, Bruno G. Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations. Adv Neural 1987; 45: 477-480.
3. Duvoisin RC. In: RN Rosenberg, ed. Comprehensive Neurology. New York: Raven Press, 1991: 337-364.
4. De Yebens JG, Fahn S, Mena MA, Pardo B, Casarejos MJ. Intracerebroventricular infusion of dopamine and its agonists in rodents and primates: an experimental approach to the treatment of Parkinson's disease. ASAIO Trans 1988; 34: 951-957.
5. Becker JB, Robinson TE, Barton P, Sintov A, Siden R, Levy RJ. Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. Brain Res. 1990; 508: 60-64.
6. Emerkh DF, Winn SR, Christenson L, Palmatier MA, Gentile FT, Sanberg PR. A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy. Neurosci Biobehav Rev 1992; 16: 437-447.
7. Perlow MJ. Brain grafting as a treatment for Parkinson's disease. Neurosurgery 1987; 20: 335-342.
8. Freed CR, Breeze RE, Rosenberg NL et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. New Engl J Med 1992; 327: 1549-1555.
9. Spencer DD, Robbins RJ, Naftolin F et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. New Engl J Med 1992; 327: 1541-1548.
10. Widner H, Tetrud J, Rehncrona S et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Engl J Med 1992; 327: 1556-1563.
11. Lindvall O, Rehncrona S, Brundin P et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neural 1989; 46: 615-631.
12. Fiandanca MS. Brain grafting for Parkinson's disease Experimental, clinical, and immunological considerations. Transplant 1991; 51: 549-556.
13. Freed CR, Breeze RE, Rosenthal NL et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch Nenrol 1990; 47: 505-512.
14. Freed WJ. Substantia-nigra grafts and Parkinson's disease - From animal experiments to human therapeutic trials. Restor Neural Neurosci 1991; 3: 109-134.
15. Freed WJ. Neural transplantation - Prospects for clinical use. Cell Transplant 1993; 2: 13-31.
16. Gage FH. Parkinson's disease. Fetal implants put to the tost. Nature 1993; 361: 405-406.
17. Aebischer P, Winn SR, Tresco PA, Jaeger CB, Greene LA. Transplantation of polymer encapsulated neurotransmitter secreting cells: effect of the encapsulation technique. J Biomech Engng 1991; 113: 178-183.
18. Aebischer P, Tresco PA, Winn SR, Greene LA, Jaeger CB. Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line. Exper Neurol 1991; 111: 269-275.
19. Aebischer P, Wahlberg L, Tresco PA, Winn SR. Macroencapsulation of dopamine-secreting cells by coextrusion with an organic polymer solution. Biomaterials 1991; 12: 50-56.
20. Tresco PA, Winn SR, Aebischer P. Polymer encapsulated neurotransmitter secreting cells. Potential treatment for Parkinson's disease. ASAIO J 1992; 38: 17-23.
21. Tresco PA, Winn SR, Tan S, Jaeger CB, Greene LA, Aebischer P. Polymer-encapsulated PC12 cells: long-term survival and associated reduction in lesion-induced rotational behaviour. Cell Transplant 1992; 1: 255-264.
22. Aebischer P, Winn SR, Galletti PM. Transplantation of neural tissue in polymer capsules. Brain Res 1988; 448: 364-368.
23. Sagen J. Chromaffin cell transplants for alleviation of chronic pain. ASAIO J 1992; 38: 24-28.
24. Greene LA, Rein G. Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells. Brain Res 1977; 129: 247-263.
25. Uludag H, Kharlip L, Sefton MV. Protein delivery by microencapsulated cells. Adv Drug Delivery Rev 1993; 10: 115-130.
26. Sefton MV, Stevenson WTK. Microencapsulation of live animal cells using polyacrylates. Adv Polym Sci 1993; 107: 143-157.
27. Crooks CA, Douglas JA, Broughton RL, Sefton MV. Microencapsulation of mammalian cells in a HEMA-MMA copolymer: effects on capsule morphology and permeability. J Biomed Mater Res 1990; 24: 1241-1262.
28. Uludag H, Sefton MV. Metabolic activity and proliferation of CHO cells in hydroxyethyl methacrylatemethyl methacrylate (HEMA-MMA) microcapsules. Cell Transplant 1993; 2: 175-182.
29. Mefford IN. Application of high performance liquid chromatography with electrochemical detection to neurochemical analysis: measurement of catecholamiruis, serotonin and metabolites in rat brain. J Neuro Met 1981; 3: 207-224.
30. Uludag H, Sefton MV. A colorimetric assay for cellular activity in microcapsules. Biomaterials 1990; 11: 708-712.
31. Uludag H, Sefton MV. Microencapsulated human hepatoma (HepG2) cells: in vitro growth and protein release. J Biomed Mater Ras 1993; 27: 1213-1224.
32. Wells GDM, Fisher MM, Sefton MV. Microencapsulation of viable hepatocytes in HEMA-MMA microcapsules: a preliminary study. Biomaterials 1993; 14: 615-620.
33. Sefton MV, Kharlip L. Insulin release from rat pancreatic islets microencapsulated in a HEMA-MMA polyacrylate. In: Lanza RP, Chick WL, eds. Pancreatic Islet Transplantation (VoI III, Immunoisolation of Pancreatic Islets), 107-117, RG Landes, Austin, TX (1994).
34. Babensee JE, De Boni U, Sefton MV. Morphological assessment of hepatoma cells (HepG2) microencapsulated in a HEMA-MMA copolymer with and without matrigel. J Biomed Mater Res 1992; 26: 1401-1418.
35. Sutherland RM. Importance of critical metabolites and cellular interactions in the biology of microregions of tumors. Cancer 1986; 58: 1668-1680.
36. Finlay GJ, Wilson WR, Baguley BC. Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. Eur J Clin Oncol 1986; 22: 655-662.
37. Freyer JP, Sutherland RM. In situ oxygen consumption rates of cells in V-79 multicellular spheroids during growth. J Cell Physiol 1984; 118: 53-61.
38. Freyer JP, Sutherland RM. A reduction in the in situ rates of oxygen and glucose consumption of cells in EMT6/R0 spheroids during growth. J Cell Physiol 1985; 124: 516-524.
39. Lucas CA, Edgar D, Thoenen H. Regulation of tyrosine hydroxylase and choline acetyltransferase activities by cell density in the PC12 rat pheochromocytoma clonal cell line. Exper Cell Res 1979; 121: 79-86.
40. Bethea CL, Kozak SL. Effect of extracellular matrix on PC12 cell shape and dopamine processing. Molec Cell Endocrinol 1984; 37: 319-329.
41. Bethea CL, Ronnekliev OK, Kozak SL. Extracellular matrix changes PC12 shape and processing of newly synthesized dopamine. Molec Cell Endocrinol 1987; 54: 63-79.
42. Gilman AG, Rall TW, Nies AS, Taylor P, eds. Pharmacological Basis of Therapeutics (8th edn). Oxford: Pergamon Press, 1990: 648.